A detailed history of Verition Fund Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 89,611 shares of RCUS stock, worth $1.37 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
89,611
Holding current value
$1.37 Million
% of portfolio
0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $1.31 Million - $1.66 Million
89,611 New
89,611 $1.36 Million
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $311,310 - $415,904
17,668 New
17,668 $317,000
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $5.3 Million - $7.69 Million
332,146 Added 1285.39%
357,986 $6.53 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $334,978 - $607,212
17,004 Added 192.44%
25,840 $534,000
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $3.29 Million - $4.26 Million
-141,660 Reduced 94.13%
8,836 $231,000
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $2.59 Million - $5.68 Million
150,496 New
150,496 $3.81 Million
Q1 2022

May 13, 2022

SELL
$28.92 - $41.83 $331,278 - $479,162
-11,455 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $359,457 - $555,223
11,455 New
11,455 $464,000
Q3 2020

Nov 16, 2020

SELL
$17.14 - $25.47 $671,322 - $997,583
-39,167 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$13.97 - $36.56 $3.29 Million - $8.61 Million
-235,403 Reduced 85.74%
39,167 $969,000
Q1 2020

May 15, 2020

BUY
$8.78 - $19.28 $2.41 Million - $5.29 Million
274,570 New
274,570 $3.81 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.1B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.